Reviewed by Michael Gill, B. Sc.
Image of Massachusetts General Hospital Cancer Center in Boston, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Palliative Care Intervention (PEACE) Groupfor Leukemia

Boston, MA
18+
All Sexes
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: Palliative care (PEACE) plus usual oncology care Usual care (standard oncology care) Participation in this research study is expected to last for up to 2 years. It is expected that about 90 people will take part in this research study.
Recruiting
Has No Placebo
Massachusetts General Hospital Cancer CenterPatrick C Johnson, MD
25 Multiple Myeloma Clinical Trials Near Me

What Are Multiple Myeloma Clinical Trials?

Multiple myeloma, also known as myeloma, is a plasma cell and bone marrow cancer. It develops in the bone marrow and spreads throughout the body. In this condition, the plasma cells, responsible for protecting our body against infection, grow excessively in numbers and crowd out the other normal cells in the bone marrow, such as RBCs, WBCs, and platelets.

Multiple Myeloma is a genetically complex, highly heterogeneous malignancy with significant inter- and intra-patient clonal variability. In recent years, increased interest has been shown in treating multiple myeloma because high-risk patients have not yet benefitted from therapeutic treatments. Distinguished researchers and institutes like Dana-Farber have researched to explore how myeloma cells interact with their environment within and outside the bone marrow compartment.

Why Is Multiple Myeloma Being Studied Through Clinical Trials?

Multiple myeloma has an annual incidence of approximately 30,770 cases in the United States and has a high mortality rate, leading to 12,770 deaths per year. It is the second most common hematological neoplasm in adults and comprises 1.8% of all cancers.

The reason why multiple myeloma is being studied through clinical trials is to improve treatment outcomes. High-risk patients do not respond well to novel treatments and risk relapse or progression towards an aggressive end-stage. Clinical trials aim to understand the disease better and develop new treatments.

What Are The Types of Treatments Available For Multiple Myeloma?

Clinical trials for multiple myeloma are distributed over a wide range of research, from bispecific antibodies to updates on CAR T clinical trials to a review of drugs and treatments in future settings.

However, despite research advancements, most patients eventually suffer a relapse and succumb to the disease. A recent research study Dual-targeted CAR T cells for refractory /relapsed (RR) Multiple Myeloma. The results show that BCMA- targeted CAR T cells have a high response rate in patients with RRMM with even high-risk features. Moreover, in conjunction with autologous stem cell transplantation, CD19- targeted CAR T cells also showed activity in RRMM. Such therapies attempt to kill myeloma cells and make it impossible for them to grow in the bone marrow environment.

However, many studies are also focused on reviewing drugs and treatments and evaluating whether a combination of drugs may be more effective in treating multiple myeloma.

What Are Some Recent Breakthrough Clinical Trials For Multiple Myeloma?

There have been several landmark studies involving multiple myeloma in recent years. Some of the most notable studies are:

2020: High-Risk Smoldering Multiple Myeloma - a study from Dana-Farber to confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with MM. The primary objective is to demonstrate progression-free survival and overall response rate and to assess the potential immunogenicity of isatuximab.

2019: Updates On CAR T - this study was focused on Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7), and light chains are in active development for therapy of refractory /relapsed (RR) MM. CD19- targeted CAR T cells in conjunction with autologous stem cell transplantation showed activity in RRMM.

Who Are Some Of The Key Opinion Institutions Conducting Multiple Myeloma Clinical Trial Research?

Multiple Myeloma Research Consortium® (MMRC®)

Multiple Myeloma Research Consortium brings together the best cancer centers globally and leverages a collaborative research model to accelerate discovery and rapidly advance medicine.

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute has a large, international team of laboratory-based and clinical investigators who strive to find more effective therapies for multiple myeloma and a cure for the future.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: January 29th, 2023